drugset / Trial / NCT06651593
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
Phase 2
Recruiting
40 enrolled
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.
Timeline
- Start
- 2025-07-02
- Primary completion
- 2028-09-01
- Completion
- 2030-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | SAR444881 | Unknown | — | Intravenous |